J Hirsh

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi request reprint Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jack Hirsh
    Henderson Research Centre, 711 Concession St, Hamilton, ON L8V 1C3, Canada
    Chest 126:188S-203S. 2004
  2. ncbi request reprint Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective
    J Hirsh
    Hamilton Civic Hospitals Research Centre, Henderson Division, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada
    Ann Intern Med 134:409-17. 2001
  3. ncbi request reprint Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies
    Jack Hirsh
    The Henderson Research Centre, Hamilton, Ontario, Canada
    Arch Intern Med 164:2106-10. 2004
  4. ncbi request reprint New anticoagulants
    J Hirsh
    Hamilton Civic Hospitals Research Centre and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
    Am Heart J 142:S3-8. 2001
  5. ncbi request reprint Laboratory monitoring of low-molecular-weight heparin therapy
    J Hirsh
    Hamilton Civic Hospital Research Center, Hamilton, Ontario, Canada
    J Thromb Haemost 2:1003. 2004
  6. ncbi request reprint Treatment of heparin-induced thrombocytopenia: a critical review
    Jack Hirsh
    Henderson Research Centre, Henderson Hospital, and the Department of Medicine, McMaster University, Hamilton, Ontario
    Arch Intern Med 164:361-9. 2004
  7. ncbi request reprint How we diagnose and treat deep vein thrombosis
    Jack Hirsh
    Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 99:3102-10. 2002
  8. ncbi request reprint Advances and contemporary issues in prophylaxis for deep vein thrombosis
    Jack Hirsh
    McMaster University, Hamilton, Ontario, Canada
    Chest 124:347S-348S. 2003
  9. ncbi request reprint New anticoagulants
    Jack Hirsh
    Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada
    Blood 105:453-63. 2005
  10. ncbi request reprint Risk of thrombosis with lenalidomide and its prevention with aspirin
    Jack Hirsh
    Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada
    Chest 131:275-7. 2007

Collaborators

Detail Information

Publications80

  1. ncbi request reprint Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jack Hirsh
    Henderson Research Centre, 711 Concession St, Hamilton, ON L8V 1C3, Canada
    Chest 126:188S-203S. 2004
    ..The synthetic pentasaccharide fondaparinux is a promising new antithrombotic agent for the prevention and treatment of venous thromboembolism...
  2. ncbi request reprint Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective
    J Hirsh
    Hamilton Civic Hospitals Research Centre, Henderson Division, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada
    Ann Intern Med 134:409-17. 2001
    ..The studies are discussed from a historical perspective, and an attempt is made to analyze both the thought processes that prompted their design and the reasons why they changed practice...
  3. ncbi request reprint Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies
    Jack Hirsh
    The Henderson Research Centre, Hamilton, Ontario, Canada
    Arch Intern Med 164:2106-10. 2004
    ..High-risk groups in the CAPRIE and CURE studies would be expected to derive enhanced benefit from treatment with clopidogrel over that achieved by ASA...
  4. ncbi request reprint New anticoagulants
    J Hirsh
    Hamilton Civic Hospitals Research Centre and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
    Am Heart J 142:S3-8. 2001
    ..Heparin and coumarins have been in clinical use for more than 50 years. Low-molecular-weight heparins (including a heparinoid), developed 25 years ago, have been used clinically for more than a decade...
  5. ncbi request reprint Laboratory monitoring of low-molecular-weight heparin therapy
    J Hirsh
    Hamilton Civic Hospital Research Center, Hamilton, Ontario, Canada
    J Thromb Haemost 2:1003. 2004
  6. ncbi request reprint Treatment of heparin-induced thrombocytopenia: a critical review
    Jack Hirsh
    Henderson Research Centre, Henderson Hospital, and the Department of Medicine, McMaster University, Hamilton, Ontario
    Arch Intern Med 164:361-9. 2004
    ....
  7. ncbi request reprint How we diagnose and treat deep vein thrombosis
    Jack Hirsh
    Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Blood 99:3102-10. 2002
    ..Several new anticoagulants with theoretical advantages over existing agents are undergoing evaluation in phase 3 studies in patients with venous thromboembolism...
  8. ncbi request reprint Advances and contemporary issues in prophylaxis for deep vein thrombosis
    Jack Hirsh
    McMaster University, Hamilton, Ontario, Canada
    Chest 124:347S-348S. 2003
  9. ncbi request reprint New anticoagulants
    Jack Hirsh
    Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada
    Blood 105:453-63. 2005
    ..Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed...
  10. ncbi request reprint Risk of thrombosis with lenalidomide and its prevention with aspirin
    Jack Hirsh
    Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada
    Chest 131:275-7. 2007
    ..There is, therefore, a critical need to incorporate a randomized comparison of aspirin with an anticoagulant in future trials evaluating lenalidomide in multiple myeloma...
  11. ncbi request reprint Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:141S-159S. 2008
    ..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients...
  12. doi request reprint Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial
    J A M Anderson
    Division of Hematology, and Cardiology, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 8:243-9. 2010
    ..The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain...
  13. ncbi request reprint Beyond unfractionated heparin and warfarin: current and future advances
    Jack Hirsh
    Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
    Circulation 116:552-60. 2007
  14. ncbi request reprint Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial
    M A Crowther
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Lancet 356:1551-3. 2000
    ..We aimed to assess whether treatment with vitamin K is safe and more effective than placebo in rapidly lowering the international normalised ratio (INR) into the therapeutic range in over anticoagulated patients receiving warfarin...
  15. ncbi request reprint Vasoflux, a new anticoagulant with a novel mechanism of action
    J I Weitz
    Hamilton Civic Hospitals Reseach Centre, Hamilton, Ontario, Canada
    Circulation 99:682-9. 1999
    ..Heparin does not inactivate fibrin-bound thrombin, whereas hirudin fails to block thrombin generation. In contrast, Vasoflux is a novel anticoagulant that inactivates fibrin-bound thrombin and attenuates factor Xa generation...
  16. ncbi request reprint Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times
    S S Anand
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arch Intern Med 159:2029-32. 1999
    ..The presence of an association between early subtherapeutic activated partial thromboplastin times (aPTTs) and recurrent venous thromboembolism (VTE) remains controversial...
  17. ncbi request reprint Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study
    J A Cairns
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Circulation 94:1553-60. 1996
    ..Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems...
  18. ncbi request reprint Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer
    P S Wells
    Department of Medicine, University of Ottawa, Ontario, Canada
    Thromb Haemost 83:416-20. 2000
    ..The combination of a score < or =4.0 by our simple clinical prediction rule and a negative SimpliRED D-Dimer result may safely exclude PE in a large proportion of patients with suspected PE...
  19. ncbi request reprint Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin
    Sonia S Anand
    McMaster Clinic Population Health Section, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
    Circulation 107:2884-8. 2003
    ..Therefore, it is unclear whether there is an association between recurrent CV events and low APTT values and between bleeding and high APTT values...
  20. ncbi request reprint Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase
    J A Anderson
    Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
    J Biol Chem 276:9755-61. 2001
    ..These studies reveal that sLA-LMWH acts as a potent antithrombin-independent inhibitor of coagulation by attenuating intrinsic tenase and prothrombinase...
  21. ncbi request reprint Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin
    S M Bates
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arch Intern Med 161:385-91. 2001
    ..We sought to identify an aPTT ratio that corresponds to therapeutic anti--factor Xa heparin levels for combinations of several reagents and coagulometers that are commonly used...
  22. ncbi request reprint Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism
    Clive Kearon
    McMaster University and the Henderson Research Centre, Hamilton, Ontario
    JAMA 296:935-42. 2006
    ..However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous thromboembolism...
  23. pmc Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study
    J S Ginsberg
    Department of Medicine, McMaster University, Hamilton, Ont
    CMAJ 160:1303-6. 1999
    ..This study was performed to determine whether intermittent compression therapy with an extremity pump benefits patients with this condition and, if so, whether the benefit is sustained...
  24. ncbi request reprint Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
    C Kearon
    McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 2:743-9. 2004
    ..Retrospective analyses suggest that 1 month of anticoagulation is adequate for patients whose venous thromboembolic event was provoked by a transient risk factor...
  25. ncbi request reprint A randomized trial comparing 5-mg and 10-mg warfarin loading doses
    M A Crowther
    Hamilton Civic Hospitals Research Centre, Ontario, Canada
    Arch Intern Med 159:46-8. 1999
    ....
  26. doi request reprint Irbesartan in patients with atrial fibrillation
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 364:928-38. 2011
    ..The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk...
  27. doi request reprint Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients
    M Sobieraj-Teague
    Flinders Medical Centre, Bedford Park, SA, Australia
    J Thromb Haemost 10:229-35. 2012
    ..Patients undergoing neurosurgical procedures are at risk of venous thromboembolism (VTE), but often have contraindications for anticoagulant prophylaxis...
  28. ncbi request reprint Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study
    M A Crowther
    Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada
    Thromb Haemost 85:390-4. 2001
    ..Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence...
  29. ncbi request reprint Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing
    C Kearon
    McMaster University Clinic, Room 401, Henderson General Hospital, 711 Concession Street; Hamilton, Ontario L8V 1C3, Canada
    Ann Intern Med 135:108-11. 2001
    ..9% to 100%]). CONCLUSION: The combination of a low pretest probability of deep venous thrombosis and a negative result on a whole-blood D -dimer test rules out deep venous thrombosis in a large proportion of symptomatic outpatients...
  30. ncbi request reprint Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Shannon M Bates
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
    Chest 133:844S-886S. 2008
    ....
  31. doi request reprint A guide to GRADE guidelines for the readers of JTH
    G Guyatt
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 11:1603-8. 2013
    ....
  32. doi request reprint Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Alexander G G Turpie
    McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Lancet 373:1673-80. 2009
    ..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty...
  33. ncbi request reprint New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jeffrey I Weitz
    Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
    Chest 126:265S-286S. 2004
    ....
  34. ncbi request reprint Diagnosis and treatment of venous thromboembolism
    Agnes Y Y Lee
    Department of Medicine, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada
    Annu Rev Med 53:15-33. 2002
    ..Aspects of thrombosis treatment that remain controversial include vena caval interruption and the indications for thrombolysis and surgical thromboembolectomy...
  35. ncbi request reprint New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jeffrey I Weitz
    Henderson Research Center, McMaster University, 711 Concession Street, Hamilton, Ontario, Canada
    Chest 133:234S-256S. 2008
    ....
  36. ncbi request reprint An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients
    Theodore E Warkentin
    McMaster University, The Henderson Research Centre, and the Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada
    Arch Intern Med 163:2518-24. 2003
    ..We sought to determine an improved definition of thrombocytopenia indicating HIT in postoperative orthopedic patients, including its impact on frequency and thrombotic risk of HIT...
  37. ncbi request reprint Current anticoagulant therapy--unmet clinical needs
    Jack Hirsh
    Department of Medicine, Hamilton Civic Hospitals Research Centre, and McMaster University, Hamilton, Ontario, Canada
    Thromb Res 109:S1-8. 2003
    ..The mechanism of action and properties of these new anticoagulants and their potential to replace those in current use will be reviewed here...
  38. ncbi request reprint A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
    Mark A Crowther
    Department of Medicine, McMaster University, Hamilton, Ont, Canada
    N Engl J Med 349:1133-8. 2003
    ..0. However, there are no prospective data to support this approach to thromboprophylaxis...
  39. doi request reprint Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides
    Jack Hirsh
    John W Eikelboom, Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada, E mail
    Thromb Haemost 111:10-3. 2014
    ..Therefore when used as a measure of efficacy in trials of thromboprophylaxis, venography has limitations for comparing the relative effects of alternative antithrombotic agents on outcomes important to patients...
  40. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  41. ncbi request reprint Prevention and treatment of postphlebitic syndrome: results of a 3-part study
    J S Ginsberg
    Department of Medicine, McMaster University Medical Center, 1200 Main St W, HSC-3W11, Hamilton, Ontario, Canada L8N 3Z5
    Arch Intern Med 161:2105-9. 2001
    ..99). CONCLUSIONS: Most patients do not have PPS 1 year after proximal DVT, and do not require stockings. We failed to show a benefit of stockings in patients with PPS, but the small numbers preclude definitive conclusions...
  42. doi request reprint Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    ..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...
  43. ncbi request reprint Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Kevin H T Teoh
    Department of Surgery, McMaster University, Hamilton, Ontario, Canada
    J Thorac Cardiovasc Surg 128:211-9. 2004
    ....
  44. doi request reprint American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 135:513-20. 2009
    ....
  45. ncbi request reprint In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation
    Lori Ann Linkins
    Henderson Research Centre and McMaster University, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3
    Thromb Res 107:241-4. 2002
    ..The ACT and aPTT therefore cannot be used to monitor low-molecular weight heparin or fondaparinux, highlighting the need for a point-of-care anti-factor Xa assay...
  46. ncbi request reprint Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review
    Martin O'Donnell
    Henderson Research Centre, Hamilton, Ontario, Canada
    Arch Intern Med 163:1362-6. 2003
    ....
  47. ncbi request reprint Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Hamilton Civic Hospitals, Hamilton, Ontario, Canada
    Chest 133:110S-112S. 2008
    ....
  48. ncbi request reprint Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Chest 127:1857-61. 2005
    ....
  49. doi request reprint Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
    Nina C Raju
    Thrombosis Service, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L2X2, Canada
    Nat Clin Pract Cardiovasc Med 5:766-80. 2008
    ..The nonthienopyridine P2Y(12) inhibitors AZD6140 and cangrelor are presently being evaluated in phase III, randomized, controlled trials...
  50. doi request reprint Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    Guillaume Pare
    Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 363:1704-14. 2010
    ....
  51. ncbi request reprint New oral anticoagulants: not quite there yet
    Ganesan Karthikeyan
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Pol Arch Med Wewn 119:53-8. 2009
    ..In this review, we attempt to provide a balanced perspective on the relative merits and demerits of the new, orally active anticoagulants, and speculate on the future of these agents in clinical practice...
  52. doi request reprint Reversal of the anti-platelet effects of aspirin and clopidogrel
    C Li
    Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    J Thromb Haemost 10:521-8. 2012
    ..Guidelines recommend stopping aspirin and clopidogrel 7 to 10 days before surgery to allow time for replacement of permanently inhibited platelets by newly released uninhibited platelets...
  53. ncbi request reprint Developing a novel antithrombotic in the academic environment
    J Hirsh
    Hamilton Civic Hospital Research Center and McMaster University, Hamilton, Ontario, Canada
    Semin Hematol 38:4-11. 2001
    ..Since their creation, Vascular Therapeutics and Osteokine have attracted major funding and developed several patentable compounds that show clinical and commercial promise...
  54. ncbi request reprint Combined antiplatelet and anticoagulant therapy: clinical benefits and risks
    J W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, ON, Canada
    J Thromb Haemost 5:255-63. 2007
    ..Whether the benefits of triple therapy outweigh the risks in patients with atrial fibrillation and coronary stents requires evaluation in randomized trials...
  55. ncbi request reprint Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk patients awaiting elective coronary artery bypass graft surgery. A randomized, controlled trial
    H M Arthur
    McMaster University, Faculty of Health Sciences and Hamilton Health Sciences Corporation, Ontario, Canada
    Ann Intern Med 133:253-62. 2000
    ..In publicly funded health care systems, a waiting period for such services as coronary artery bypass graft surgery (CABG) is common. The possibility of using the waiting period to improve patient outcomes should be investigated...
  56. ncbi request reprint Monitoring unfractionated heparin with the aPTT: time for a fresh look
    John W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:547-52. 2006
    ..However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies...
  57. doi request reprint Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh
    Hamilton Civic Hospitals, Hamilton, Ontario, Canada
    Chest 133:71S-109S. 2008
  58. doi request reprint Guidelines for anticoagulant use in acute coronary syndromes
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, Ont, Canada, L8L 2X2
    Lancet 371:1559-61. 2008
  59. ncbi request reprint Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial
    John A Cairns
    University of British Columbia, Vancouver, British Columbia, Canada
    Am Heart J 155:33-41. 2008
    ....
  60. ncbi request reprint Establishing an optimal therapeutic range for coumarins: filling in the gaps
    Martin O'Donnell
    Arch Intern Med 164:588-90. 2004
  61. ncbi request reprint Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
    ..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population...
  62. ncbi request reprint Randomized trial of warfarin nomograms
    Mark A Crowther
    Ann Intern Med 140:490; author reply 491-2. 2004
  63. ncbi request reprint Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
    Carlo Patrono
    ESC Task Force on Antiplatelets, University of Rome La Sapienza, II Facolta di Medicina e Chirurgia, Via di Grottarossa, 1035, 00189 Roma, Italy
    Eur Heart J 25:166-81. 2004
  64. ncbi request reprint Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery
    Gary E Raskob
    College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, 801 NE Thirteenth Street, Room 139, Oklahoma City, OK 73104, USA
    Chest 124:379S-385S. 2003
    ....
  65. ncbi request reprint Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry
    Frederick A Anderson
    Center for Outcomes Research, Department of Surgery, University of Massachusetts Medical School, 365 Plantation Street, Suite 185, Worcester, MA, USA
    Chest 124:349S-356S. 2003
    ..We examined trends in the use of prophylaxis for venous thromboembolism (VTE) among patients who underwent primary total hip arthroplasty (THA) or total knee arthroplasty (TKA)...
  66. ncbi request reprint Is impaired renal function a contraindication to the use of low-molecular-weight heparin?
    Jeff Nagge
    Toronto General Hospital, Eaton North Wing G 260, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
    Arch Intern Med 162:2605-9. 2002
    ..50 mL/s) should be excluded from treatment with low-molecular-weight (LMW) heparin, or have anti-factor Xa heparin level monitoring performed...
  67. ncbi request reprint The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
    Chest 126:204S-233S. 2004
    ....
  68. ncbi request reprint Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Shannon M Bates
    McMaster University Medical Center, 1200 Main St West, Hamilton, ON L8N 325
    Chest 126:627S-644S. 2004
    ..In high-risk women with prosthetic heart valves, we suggest the addition of low-dose aspirin, 75 to 162 mg/d (Grade 2C)...
  69. doi request reprint Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines
    Jack Hirsh
    Chest 133:1293-5. 2008
  70. ncbi request reprint Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Carlo Patrono
    University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy
    Chest 126:234S-264S. 2004
    ....
  71. pmc Anticoagulation for venous thromboembolism
    John W Eikelboom
    BMJ 334:645. 2007
  72. ncbi request reprint Heparin resistance in acute coronary syndromes
    Jonathan D Rich
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Thromb Thrombolysis 23:93-100. 2007
    ..Direct thrombin inhibitors may offer an advantage in more predictable anticoagulation...
  73. ncbi request reprint Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA
    Chest 133:160S-198S. 2008
    ..Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B)...
  74. ncbi request reprint Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Carlo Patrono
    Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Chest 133:199S-233S. 2008
    ....
  75. ncbi request reprint Perioperative management of patients receiving oral anticoagulants
    Clive Kearon
    Arch Intern Med 163:2532-3; author reply 2533. 2003
  76. ncbi request reprint Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin
    Robert Raschke
    Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, Arizona 85006, USA
    Ann Intern Med 138:720-3. 2003
    ..Therapeutic ranges of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents...
  77. ncbi request reprint American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    Jack Hirsh
    Circulation 107:1692-711. 2003
  78. ncbi request reprint Electrical foot stimulation and implications for the prevention of venous thromboembolic disease
    Robert E Kaplan
    Department of Pediatrics, State University of New York, Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA
    Thromb Haemost 88:200-4. 2002
    ..A safe and convenient method for reducing venous stasis would be useful in patients while in hospital and after discharge during their rehabilitation...
  79. ncbi request reprint [Expert consensus document on the use of antiplatelet agents]
    Carlo Patrono
    Rev Esp Cardiol 57:963-80. 2004
  80. ncbi request reprint American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    Jack Hirsh
    J Am Coll Cardiol 41:1633-52. 2003